Enzo Biochem to Announce Third Quarter 2020 Financial Results on Monday June 8, 2020
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Enzo Biochem, Inc. (NYSE: ENZ) will announce its third quarter 2020 financial results on June 8, 2020, after market close. Following the release, President Barry Weiner and CFO David Bench will host a conference call at 5:00 PM ET to discuss the financial results and address investor questions. The call will be accessible via an audio webcast.
Positive
- Scheduled release of third quarter 2020 financial results indicates ongoing transparency to investors.
Negative
- None.
Details
News Market Reaction – ENZ
The recorded move for ENZ in the trading session of this news was -8.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, NY, June 03, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) a leading biosciences and diagnostics company, today announced that it will release its third quarter 2020 financial results after the market closes on Monday June 8, 2020. The company’s President Barry Weiner and Chief Financial Officer David Bench will host a conference call for the investment community the same day at 5:00 PM ET (2:00 PM PT) to discuss the results and answer questions.
The call can be accessed through a live audio webcast and through a live conference call by dialing +1 323-794-2590 using the conference code 9751599. An archived webcast of the conference call will also be available on the Enzo Investor Relations website following the call.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
###
Contact:
For Enzo Biochem, Inc.
David Bench, CFO
212-583-0100
dbench@enzo.com
Investors/Media:
Melanie Solomon
The Blueshirt Group
415-217-4964
melanie@blueshirtgroup.com
Steve Anreder
Anreder & Company
212-532-3232
Steven.anreder@anreder.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.